Related references
Note: Only part of the references are listed.Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages
Reiko Okutsu et al.
ATHEROSCLEROSIS (2009)
Where are we with probucol: A new life for an old drug?
Shizuya Yamashita et al.
ATHEROSCLEROSIS (2009)
The apolipoprotein A5-1131T>C promoter polymorphism in Koreans: Association with plasma APOA5 and serum triglyceride concentrations, LDL particle size and coronary artery disease
Yangsoo Jang et al.
CLINICA CHIMICA ACTA (2009)
Effects of Statin Treatments on Coronary Plaques Assessed by Volumetric Virtual Histology Intravascular Ultrasound Analysis
Myeong-Ki Hong et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2009)
Effect of Fluvastatin on Progression of Coronary Atherosclerotic Plaque Evaluated by Virtual Histology Intravascular Ultrasound
Kenya Nasu et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2009)
Probucol markedly reduces HDL phospholipids and elevated preβ1-HDL without delayed conversion into α-migrating HDL: Putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling
Takashi Miida et al.
ATHEROSCLEROSIS (2008)
Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial
Jean-Claude Tardif et al.
ATHEROSCLEROSIS (2008)
Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque
Patrick W. Serruys et al.
CIRCULATION (2008)
Is It LDL Particle Size or Number that Correlates with Risk for Cardiovascular Disease?
H. Robert Superko et al.
CURRENT ATHEROSCLEROSIS REPORTS (2008)
Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet
T. Yoshikawa et al.
HORMONE AND METABOLIC RESEARCH (2008)
Long-Term Probucol Treatment Prevents Secondary Cardiovascular Events: a Cohort Study of Patients with Heterozygous Familial Hypercholesterolemia in Japan
Shizuya Yamashita et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2008)
Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells
So Youn Park et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2008)
Accuracy of in vivo coronary plaque morphology assessment - A validation study of in vivo virtual histology compared with in vitro histopathology
Kenya Nasu et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis - The ASTEROID trial
SE Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The vascular effects of cilostazol
William S. Weintraub
CANADIAN JOURNAL OF CARDIOLOGY (2006)
Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism
K Hirano et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: A randomized prospective study
M Yokoyama et al.
AMERICAN HEART JOURNAL (2005)
Probucol promotes functional reendothelialization in balloon-injured rabbit aortas
AK Lau et al.
CIRCULATION (2003)
Coronary plaque classification with intravascular ultrasound radiofrequency data analysis
A Nair et al.
CIRCULATION (2002)
Effects of Probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia - Fukuoka Atherosclerosis Trial (FAST)
Y Sawayama et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells
KY Kim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta
T Nakamura et al.
LIFE SCIENCES (2001)
Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats
T Tani et al.
ATHEROSCLEROSIS (2000)
Share Paper
